ATE480622T1 - Bildgebende verfahren, diagnose und behandlung von krankheiten - Google Patents

Bildgebende verfahren, diagnose und behandlung von krankheiten

Info

Publication number
ATE480622T1
ATE480622T1 AT06077262T AT06077262T ATE480622T1 AT E480622 T1 ATE480622 T1 AT E480622T1 AT 06077262 T AT06077262 T AT 06077262T AT 06077262 T AT06077262 T AT 06077262T AT E480622 T1 ATE480622 T1 AT E480622T1
Authority
AT
Austria
Prior art keywords
diagnosis
treatment
diseases
imaging procedures
imaging
Prior art date
Application number
AT06077262T
Other languages
English (en)
Inventor
Lukasz Huminiecki
Roy Bicknell
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of ATE480622T1 publication Critical patent/ATE480622T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
AT06077262T 2000-11-06 2001-11-06 Bildgebende verfahren, diagnose und behandlung von krankheiten ATE480622T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24556600P 2000-11-06 2000-11-06
US27366201P 2001-03-07 2001-03-07

Publications (1)

Publication Number Publication Date
ATE480622T1 true ATE480622T1 (de) 2010-09-15

Family

ID=26937319

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06077262T ATE480622T1 (de) 2000-11-06 2001-11-06 Bildgebende verfahren, diagnose und behandlung von krankheiten
AT01992777T ATE360068T1 (de) 2000-11-06 2001-11-06 Bildgebende verfahren, diagnose und behandlung von krankheiten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01992777T ATE360068T1 (de) 2000-11-06 2001-11-06 Bildgebende verfahren, diagnose und behandlung von krankheiten

Country Status (12)

Country Link
US (5) US7498034B2 (de)
EP (2) EP1334194B1 (de)
JP (2) JP2004524821A (de)
AT (2) ATE480622T1 (de)
AU (3) AU2002223784B2 (de)
CA (1) CA2427310C (de)
CY (2) CY1107609T1 (de)
DE (2) DE60143065D1 (de)
DK (2) DK1334194T3 (de)
ES (1) ES2296829T3 (de)
PT (2) PT1790728E (de)
WO (1) WO2002036771A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498034B2 (en) * 2000-11-06 2009-03-03 Cancer Research Technology Limited Imaging, diagnosis and treatment of disease
ES2390425T3 (es) * 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
WO2004003163A2 (en) * 2002-06-27 2004-01-08 University Of Utah Research Foundation Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
US7185814B2 (en) * 2002-10-16 2007-03-06 Dcard, Inc. Layer structure and method of manufacture for optical memory strip (OMS)
US20060099143A1 (en) * 2002-11-20 2006-05-11 Roy Bicknell Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition angiogenesis
CN101277974A (zh) * 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
US7465312B2 (en) 2006-05-02 2008-12-16 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
WO2007130465A2 (en) * 2006-05-02 2007-11-15 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
KR20090089462A (ko) * 2006-12-11 2009-08-21 유니버시티 오브 유타 리써치 파운데이션 병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법
AR065271A1 (es) 2007-02-09 2009-05-27 Genentech Inc Anticuerpos anti-robo4 y sus usos
US8399421B2 (en) * 2007-03-30 2013-03-19 The Board Of Regents Of The University Of Texas System Treatment for neuropathic pain due to spinal cord injury
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
WO2009046127A1 (en) * 2007-10-01 2009-04-09 Allos Therapeutics, Inc. Dt-diaphorase-active agents for treatment of pediatric tumors
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
HUE028878T2 (en) 2009-09-03 2017-01-30 Cancer Res Tech Ltd CLEC14A inhibitors
US9512481B2 (en) 2009-09-11 2016-12-06 The Regents Of The University Of Colorado, A Body Corporate Polymorphisms in the PDE3A gene
US20110105735A1 (en) * 2009-10-29 2011-05-05 Heather Desaire Methods of producing and purifying proteins
CN102656190A (zh) * 2009-12-08 2012-09-05 雅培股份有限两合公司 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
NZ714482A (en) 2012-01-27 2017-08-25 Abbvie Inc Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
MX356749B (es) * 2012-04-27 2018-06-12 Daiichi Sankyo Co Ltd Anticuerpo anti-homologo 4 de roundabout (robo4).
JP6445446B2 (ja) * 2012-11-08 2018-12-26 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 骨転移の治療のための方法及び医薬組成物
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
JP7267998B2 (ja) * 2017-08-19 2023-05-02 オハイオ・ステイト・イノベーション・ファウンデーション 新規ペプチド系癌造影剤
CN115023144A (zh) 2019-10-25 2022-09-06 循环食品技术私人有限责任公司 包含啤酒糟的液体部分的液体食品
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069007A (en) * 1989-06-21 2000-05-30 City Of Hope Ribozyme cleavage of HIV RNA
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
EP0682113A3 (de) 1994-05-12 1996-12-18 Ono Pharmaceutical Co Polypeptide hergestellt in einer Endothel Zell-Linie und dafür kodierende DNS.
WO2000053756A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999006423A1 (en) 1997-07-30 1999-02-11 Human Genome Sciences, Inc. 83 human secreted proteins
US20040002591A1 (en) * 1997-09-05 2004-01-01 Human Genome Sciences, Inc. 50 human secreted proteins
EP1019091A4 (de) * 1997-09-05 2005-05-11 Human Genome Sciences Inc 50 menschliche sekretierte proteine
US6225118B1 (en) * 1997-10-01 2001-05-01 Biocure Limited Multicellular in vitro assay of angiogenesis
JP3868740B2 (ja) * 1998-03-10 2007-01-17 ジェネンテック・インコーポレーテッド 新規なポリペプチド及びそれをコードする核酸
JP2002511259A (ja) 1998-04-09 2002-04-16 ジェンセット ５’ｅｓｔおよびコードされるヒトタンパク質
EP1074617A3 (de) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers für Synthese von ganzen-Länge cDNS und deren Anwendung
EP1210370A4 (de) * 1999-08-12 2004-06-09 Human Genome Sciences Inc Menschlicher tumornekrosefaktor-rezeptor tr16
AU1190801A (en) 1999-09-30 2001-04-30 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US7498034B2 (en) * 2000-11-06 2009-03-03 Cancer Research Technology Limited Imaging, diagnosis and treatment of disease
SI1572169T1 (sl) * 2002-03-08 2013-12-31 Shanghai Institutes For Biological Sciences, Cas Odkrivanje in modulacija slit in robo posredovane angiogeneze ter njuni načini uporabe
US20060099143A1 (en) * 2002-11-20 2006-05-11 Roy Bicknell Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition angiogenesis

Also Published As

Publication number Publication date
DE60127986T2 (de) 2008-01-17
AU2007201584A1 (en) 2007-05-03
JP5603145B2 (ja) 2014-10-08
US20070025913A1 (en) 2007-02-01
EP1790728B1 (de) 2010-09-08
US20040071711A1 (en) 2004-04-15
US7498034B2 (en) 2009-03-03
DE60143065D1 (de) 2010-10-21
WO2002036771A2 (en) 2002-05-10
PT1334194E (pt) 2007-07-17
AU2378402A (en) 2002-05-15
EP1334194A2 (de) 2003-08-13
US20090191572A1 (en) 2009-07-30
CA2427310A1 (en) 2002-05-10
ATE360068T1 (de) 2007-05-15
EP1334194B1 (de) 2007-04-18
EP1790728A3 (de) 2007-06-13
US20080145359A1 (en) 2008-06-19
JP2004524821A (ja) 2004-08-19
CA2427310C (en) 2013-12-17
CY1110967T1 (el) 2015-06-11
ES2296829T3 (es) 2008-05-01
WO2002036771A3 (en) 2002-09-06
EP1790728A2 (de) 2007-05-30
PT1790728E (pt) 2010-11-12
DK1334194T3 (da) 2007-05-29
US7582440B2 (en) 2009-09-01
AU2002223784B2 (en) 2007-01-18
US20080219924A1 (en) 2008-09-11
US20080274045A9 (en) 2008-11-06
CY1107609T1 (el) 2013-03-13
US8216584B2 (en) 2012-07-10
JP2010248210A (ja) 2010-11-04
US7740830B2 (en) 2010-06-22
DK1790728T3 (da) 2010-12-06
DE60127986D1 (de) 2007-05-31

Similar Documents

Publication Publication Date Title
ATE480622T1 (de) Bildgebende verfahren, diagnose und behandlung von krankheiten
ATE441663T1 (de) Verfahren und zusammensetzungen für amyloidosis- verbundene krankheiten
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
ATE510562T1 (de) Anti-ailim antikörper zur behandlung von crohn's
DE60237725D1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
CY1115117T1 (el) Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα
DE60022754D1 (de) Diagnose und behandlung von arrhythmien
CY1110505T1 (el) Ανθρωπινα αντισωματα dr4 και χρησεις αυτων
DE60027415D1 (de) Zusammensetzung für die Verhinderung der Glattmuskelkrankheiten, die Ascorbat, Arginin und Magnesium enthält
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
EP1505990A4 (de) Verfahren zur behandlung von hepatitis
EP1539251A4 (de) Zusammensetzungen und verfahren zur diagnose und therapie von medizinischen erkrankungen mit angiogenese
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE59310320D1 (de) Neue Mittel zur Diagnose von Gefässerkrankungen
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
ATE395919T1 (de) Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE60125212D1 (de) Verwendung von Aivlosin zur Behandlung und Prevention der Lawsonia-Infektionen in Schweinen.
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
DE60225845D1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie
ATE313628T1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1790728

Country of ref document: EP